Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering Formulation for Neuroimaging Agent, NAV5001

  Navidea Biopharmaceuticals Announces Issuance of New U.S. Patent Covering
  Formulation for Neuroimaging Agent, NAV5001

Business Wire

DUBLIN, Ohio -- November 14, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that the
U.S. Patent and Trademark Office (USPTO) has issued a new patent covering the
formulation of the Company’s radiolabeled dopamine transporter (DAT) receptor
ligand, NAV5001, used with SPECT imaging for potential differential diagnosis
of Parkinsonian Syndromes and Dementia with Lewy Bodies. The patent
(8,574,545) is set to expire in 2031.

The new U.S. patent, “Labeled Iodinated Tropane Formulation,” extends the
scope and longevity of the NAV5001 intellectual property (IP) portfolio. The
high concentration formulation protected by this patent may afford greater
commercial flexibility and manufacturing efficiency to optimize distribution.
Navidea anticipates commencing the NAV5001 Phase 3 clinical program by year
end. This new patent reinforces the Company’s NAV5001 platform alongside
previously issued U.S. Patent 8,084,018, “Methods for Imaging Dopamine
Transporter Level,” which covers the acquisition of Dopamine Transporter SPECT
images soon after injection of NAV5001, a unique feature and competitive
advantage for NAV5001. These patents were issued to Alseres Pharmaceuticals
and have been licensed exclusively to Navidea.

About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing multiple
precision diagnostic products and platforms including NAV4694, NAV5001,
Manocept™ and RIGScan^TM , to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making and, ultimately, patient care. Lymphoseek^® (technetium 99m
tilmanocept) Injection, ^ Navidea’s first commercial product from the Manocept
platform, was approved by the FDA in March 2013. Navidea’s strategy is to
deliver superior growth and shareholder return by bringing to market novel
radiopharmaceutical agents and advancing the Company’s pipeline through
selective acquisitions, global partnering and commercialization efforts. For
more information, please visit

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of the Company.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways, and markets for
the Company’s products are forward-looking statements within the meaning of
the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not
limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition, limited marketing
and manufacturing experience, risks of development of new products, regulatory
risks and other risks detailed in the Company’s most recent Annual Report on
Form 10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking


Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.